
Medtronic wins Canadian approval for brain-stim epilepsy therapy
Medtronic (NYSE:MDT) touted Health Canada approval for its deep brain stimulation therapy for refractory epilepsy patients. The DBS system delivers directed electrical impulses via an implanted device to a part of the brain involved in seizures.
Medtronic’s DBS won CE Mark approval for epileptic patients in the European Union in August 2010, but has yet to gain similar approval from the U.S. FDA.
The device is under humanitarian device exemption in the U.S. for a number of conditions, including treatment-resistant obsessive-compulsive disorder and advanced Parkinson’s disease. More than 85,000 patients worldwide have received Medtronic DBS therapy to date, according to a press release. Read more
Acclarent recalls Inspira AIR balloon dilation system for potential deflation defects
ImThera wins CE Mark for aura6000 obstructive sleep apnea treatment
FDA warns Life Recovery Systems for violations at New Jersey plant
Mauna Kea touts American Medical Assn. category codes for Cellvizio endoscopic microscope
PLC Systems lands Israeli regulatory approval to distribute RenalGuard
Mevion Medical lands CE Mark win for proton therapy system
Somnetics announces CE Mark for Transcend sleep apnea therapy system
Simpirica Spine wins FDA approval to begin IDE study of LimiFlex spinal stabilization
Boston Scientific touts Health Canada approval for Blazer ablation catheter
Alma Lasers lands FDA approval for laser-based Harmony(XL) nail fungus treatment